In the last few decades, immunotherapy has become an important part of treating some types of cancer. Newer types of immune treatments are now being studied, and they’ll impact how we treat cancer in the future. With the help of capital and innovation, we are eagerly looking forward to turning this treatment from research to clinic trial and making it more effective and affordable
2017 HIGHLIGHT SPEAKERS
Dr. Lodish is a MIT Professor, Founding Member of Whitehead Institute for Biomedical Research and a Member of the National Academy of Sciences. He was also a founder and scientific advisory board member of Genzyme, Inc., Arris Pharmaceuticals, Inc, Millennium Pharmaceuticals, Inc, and Allozyne, Inc. Dr. Lodish's research focuses on cell surface proteins and other important areas at the interface between molecular cell biology and medicine.
Dr. Chen is a professor at MIT, and the co-director of the Center for Infection and Immunity, the Chinese Academy of Sciences. Dr Chen’s laboratory focuses on a particular class of immune cells – CD8 T-cells –which play an important role in the ability of the immune system to respond more strongly to threats that have been encountered before.
Zhen Su, Vice President and Head of Global Medical Affairs - Oncology at EMD Serono leads medical strategy and the team for the franchise. Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served as Associate Vice President and Global Head of Jevtana® (cabazitaxel) at Sanofi.
Wei Zhao joined WuXi Healthcare Ventures (now 6 Dimensions Capital) in 2016. He was a Senior Life Sciences Specialist at L.E.K. Consulting Boston office, and a postdoctoral fellow at Mass. Eye and Ear Infirmary and Harvard Medical School. Wei obtained his Ph.D. in Neuroscience from Northwestern University, and B.S. from Tsinghua University.